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Our recent studies revealed that cell clusters overlying focal myoepithelial cell layer disruption (FMCLD) had a 
significantly higher frequency of genetic instabilities and expression of invasion-related genes than their adja-
cent counterparts within the same duct. Our current study attempted to assess whether these cell clusters would 
also have elevated c-erbB2 expression. Human breast tumors (n=50) with a high frequency of FMCLD were 
analyzed with double immunohistochemistry, real-time RT-PCR, and chromogenic in  situ hybridization for 
c-erbB2 protein and gene expression. Of 448 FMCLD detected, 404 (90.2%) were associated with cell clusters that 
had intense c-erbB2 immunoreactivities primarily in their cytoplasm, in contrast to their adjacent counterparts 
within the same duct, which had no or barely detectable c-erbB2 expression. These c-erbB2 positive cells were 
arranged as tongue-like projections, “puncturing” into the stroma, and about 20% of them were in direct conti-
nuity with tube-like structures that resembled blood vessels. Aberrant c-erbB2 expression was also seen in clus-
ters of architecturally normal-appearing ducts that had distinct cytological abnormalities in both ME and epithe-
lial cells, whereas not in their clear-cut normal counterparts. Molecular assays detected markedly higher c-erbB2 
mRNA and gene amplification in cell clusters associated with FMCLD than in those associated with 
non-disrupted ME cell layers. Our findings suggest that cell clusters overlying FMCLD may represent the pre-
cursors of pending invasive lesions, and that aberrant cerbB2 expression may trigger or signify the emergence of 
biologically more aggressive cell clones. 
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Introduction 
The epithelium of normal and pre-invasive breast 
tumors is physically separated from the stroma by 
both the myoepithelial (ME) cells and the basement 
membrane. ME cells are joined by intercellular junc-
tions and adhesion molecules, constituting a largely 
continuous sheet encircling the epithelium [1]. The 
basement membrane is composed of mainly type IV 
collagen and laminins, forming a continuous lining 
surrounding and attaching to the ME cell layer [2]. 
Because of these structural relationships, degradation 
of both the ME cell layer and the basement membrane 
is a pre-requisite for tumor invasion.   
Breast carcinogenesis is believed to be a multi-
stage process, progressing sequentially from normal to 
hyperplastic, to in situ, and to invasive stages [3]. Pro-
gression from an in situ to the invasive stage is be-
lieved to be triggered primarily by the overproduction 
of proteolytic enzymes by cancer cells, which cause 
degradation of the basement membrane [4]. These 
theories are consistent with data derived from studies 
in cell cultures or animal models [5], whereas they are 
hard to reconcile with three facts. First, a subset of Int. J. Biol. Sci. 2008, 4 
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morphologically normal breast tissues shares a similar 
immunohistochemical or genetic profile with their 
malignant counterparts [6-9]. Second, a vast majority 
of in situ tumors express high levels of proteolytic en-
zymes, but only 10-30% of the untreated in situ tumors 
progress to invasive lesions during patients’ lifetime 
[10,11]. Third, results from recent worldwide clinical 
trials of treating and preventing cancer invasion with 
a wide variety of proteolytic enzyme inhibitors have 
been very disappointing [12].   
These facts argue that alternative mechanisms 
may exist for breast tumor invasion in some cases. As 
the diagnosis of in situ breast tumors has increased by 
almost 10-fold in the US and Europe during the last 20 
years, and over 95% of cancer-related death result 
from invasion-related illness [13,14], there is an urgent 
need to identify the intrinsic mechanism of invasion 
and the specific precursor of invasive lesions.   
Promoted by the fact that the ME cell layer is the 
sole source of several tumor suppressors [15-17], and 
that ME cell degradation is the most distinct morpho-
logical sign of invasive breast lesions [1,2], our recent 
studies have attempted to identify the early signs of 
ME cell degradation.   
Our initial studies examined the physical integ-
rity of ME cell layers in 220 patients with estrogen re-
ceptor (ER) positive ductal carcinoma in situ (DCIS). Of 
5,698 ducts examined, 405 were found to harbor focal 
disruptions (the absence of ME cells resulting in a gap 
greater than the combined size of at least 3-epithelial 
cells) in surrounding ME cell layers. Compared to ad-
jacent counterparts within the same duct, but distant 
from the disruption, cell clusters overlying focal ME 
cell layer disruptions (FMCLD) had a significantly 
higher frequency of ER negativity, proliferation, ge-
netic instabilities, expression of tumor inva-
sion-related genes, and aberrant expression of cellular 
adhesion molecules [18-26].   
Together, these findings suggest that FMCLD 
may represent an early sign of ME cell degradation, 
and that cell clusters overlying FMCLD may represent 
a biologically more aggressive clone, which is at 
higher risk for invasion. Since c-erbB2 is a well docu-
mented onco-protein closely associated with tumor 
aggressiveness and invasiveness [27-29], our current 
study attempted to assess whether c-erbB2 would be 
exclusively or preferentially expressed in cell clusters 
overlying FMCLD.   
Materials and Methods 
Formalin-fixed, paraffin-embedded breast tissue 
blocks from 40 females with co-existing normal, hy-
perplastic, and DCIS components in all cases, and 10 
females with additional infiltrating ductal carcinoma 
(IDC) were used in this study. All the malignant 
components were grade I or II, and stage I or II le-
sions. These cases were selected from our previous 
studies of over 500 DCIS and IDC cases [18-26]. All the 
selected cases harbored a high frequency of FMCLD, 
based on our previous immunohistochemical studies 
[18-26].  
Consecutive sections at 5-7μm thickness were cut 
and placed on positively charged slides. The first and 
last sections were H&E stained for morphological 
classification using our published criteria [30]. Sec-
tions were subjected to double immunohistochemistry 
with mouse monoclonal antibodies against the exter-
nal domain of c-erbB2 (Novocastra, Newcastle, UK) 
and smooth muscle actin (Vector, Burlingame, CA, 
USA), a ME cell phenotypic protein using our pub-
lished protocols [31-32].   
To assess the specificity of c-erbB2 immu-
nostaining, three approached were used. First, differ-
ent controls were included: (1) substitution of the 
primary antibody with normal serum; (2) omission of 
the secondary antibody from the immunostaining se-
quence; (3) serial dilutions of the primary antibody; (4) 
inclusion of sections from normal lymph-nodes. Sec-
ond, the same immunostaining protocol was used for 
the same cases, while substituted with epitopically 
similar antibodies from different manufacturers (Lab 
Vision, Fremont, CA, USA and Dako (Glostrup, Den-
mark). Third, both the avidin-biotin-peroxidase and 
avidin-biotin-alkaline phosphatase detection kits 
(Vector, Burlingame, CA, USA) were used to assess 
the expression of c-erbB2 in consecutive sections of the 
same cases. Imunostaining was repeated at least twice. 
Immunostained sections were independently evalu-
ated by at least two investigators, to determine the 
overall expression status of c-erbB2 in different tissue 
components, and to count the actual number of 
c-erbB2 positive cells overlying each FMBLC. The 
frequency of c-erbB2 expression in morphologically 
similar ducts (the same histological type and grade, 
and similar size and shape) with and without FMCLD 
was statistically compared with the Pearson’s 
Chi-squared test. A cell was considered c-erbB2 posi-
tive, if intense (at least ++) immunoreactivities were 
seen in its membrane or cytoplasm, whereas all the 
controls were devoid of immunoreactivities.   
To correlate c-erbB2 protein expression with 
c-erbB2 mRNA levels, three cases with multiple large 
c-erbB2 positive cell clusters (≥100 cells/cluster) over-
lying FMCLD were selected. A total of 50 consecutive 
sections at 10-12µm thickness were made from each 
case. Sections 1, 11, 21, 31, and 41 were subjected to 
immunostaining as described above. The remaining 
sections were lightly stained with hematoxylin. Using Int. J. Biol. Sci. 2008, 4 
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immunostained sections as references, 
c-erbB2-positive cells overlying FMCLD and adjacent 
negative cells within the same duct, but distant from 
the disruption, were microdissected under a standard 
microscope, as previously described [21].   
Microdissected cells were subjected to RNA ex-
traction with Trizol (Invitrogen, Carlsbad, CA, USA) 
using the protocol provided by the manufacturer. 
RNA concentrations were measured with a model 
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) us-
ing the manufacturer’s Pico-RNA chip. RNA extracts 
were incubated with DNase for 15 minutes at room 
temperature before RT-PCR. For each RNA extract, 10 
µl of the RNA were reversely transcribed into cDNA 
using random hexamer primers and omniscript re-
verse transcriptase (Qiagen Technology, Germantown, 
MD, USA) in a 20μl volume.   
The cDNAs were subjected to real-time PCR. 
TaqMan MGB probes (5’-FAM dye-labeled) and 
primers were designed using the Applied Biosystems’ 
Primer Express 3.0 (Foster City, CA, USA). The se-
quences (Table 1) of primers and probes were checked 
for specificity by searching the NCBI BLAST database. 
All primers and probes are obtained from Applied 
Biosystems. These assays were designed in such a way 
that the amplified RNA sequences span over 
exon-exon junctions, consequently the sequence in the 
genome is undetectable. Real-time PCR was carried 
out using an ABI 7500 fast Sequence Detection System. 
Singleplex real-time PCR reactions were performed 
using 10ng RNA from paired samples, and the 
TaqMan® Fast Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA). A thermal cycling 
profile, consisting of an initial DNA polymerase acti-
vation for 20 seconds at 95 ºC followed by 40 cycles of 
PCR (95 ºC for 3 seconds, 60 ºC for 30 seconds) was 
used for all analyses. Changes in the gene expression 
levels were calculated using the ∆∆Ct method [33]. 
Each datum set was analyzed in triplicate, and was 
normalized by using beta-2-microglobulin as a run 
standard.  
Table 1. Primer and probe sequences used in the assays 
Part 
number 
Name Sequence  Tm 
(ºC)
GC%
4304970 HER2-F  CCTACCTGCCCACCAATGC  59.9 63 
4304970 HER2-R  GTTGTGAGCGATGAGCACGTA  58.5 52 
4316034 HER2-P  FAM-CCTGCAGGATATCCA-MGB 69.0 53 
4304970  β2M-246F TGACTTTGTCACAGCCCAAGATA 58.4 43 
4304970  β2M-330R AATCCAAATGCGGCATATTC  57.2 40 
450025  β2M-275P VIC-TGATGCTGCTTACATGTCTC 
GATCCCA-TAMRA 
68.2 48 
 
To correlate c-erbB2 protein expression with 
c-erbB2 gene amplification, tissue sections from 10 
cases (6 DCIS and 4 IDC) with elevated c-erbB2 pro-
tein expression were subjected to chromogenic in situ 
hybridization (CISH) with a c-erbB2 DNA probe, a 
tissue pretreatment kit, and a polymer detection kit 
from Zymed Laboratories, Inc (South San Francisco, 
CA, USA), following the protocol provided by the 
manufacturer. The interpretation of c-erbB2 status was 
based on a previously published criterion [34]. Using 
immunohistochemically stained sections as references, 
cell clusters overlying FMCLD and their adjacent 
counterparts within the same duct were identified in 
CISH stained sections. Pictures in these locations were 
taken under high magnification, and enlarged color 
prints were made. The number of dots in at least 60 
nuclei/per location in enlarged color printers were 
then counted and compared.   
Results  
Distinct typical membranous c-erbB2 expression 
was detected in six DCIS and four IDC. The number of 
c-erbB2 positive cells in these cases accounted for 
about 30-50% of the cancer cell population. The stro-
mal tissues and negative controls were devoid of 
c-erbB2 expression. Antibodies from different compa-
nies and different detection kits yielded similar results 
(not shown).   
Each of the 50 cases contained multiple (5 to over 
20) ducts or acini with FMCLD, and a total of 448 
FMCLD were identified. The size of FMCLD varied 
substantially, ranging from a few cells to over 50% of 
the entire ME cell layer. The size of the cell clusters 
overlying FMCLD also varied substantially, ranging 
from as few as 10 to more than 300 cells. Of the 448 
FMCLD, 404 (90.2%) were associated with cell clusters 
that had intense c-erbB2 immunoreactivities primarily 
in cytoplasm. Of 448 morphologically similar ducts 
with non-disrupted ME cell layers, only 38 (0.85%) 
showed distinct cytoplasmic c-erbB2 expression (Table 
2).  
Table 2. Comparison of aberrant c-erbB2 expression in ducts 
with and without FMCLD 
Duct type  Total number    With c-erbB2 expres-
sion 
p 
With FMCLD  448  404 (90.2%) 
W/o FMCLDD  448  38 (0.85%) 
< 0.01 
 
The distribution of c-erbB2 positive malignant or 
hyperplastic cells associated with FMCLD could be 
roughly classified into two main categories:   
1. Individual duct or small duct clusters: About 70% 
of c-erbB2 positive cell clusters were distributed in the 
individual duct or small duct clusters. Under low 
magnification, a vast majority of c-erbB2 positive 
clusters were indistinguishable from adjacent coun-
terparts within the same or different ducts. Under Int. J. Biol. Sci. 2008, 4 
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high magnification, these c-erbb2 positive cells dif-
fered noticeably from their adjacent counterparts 
within the same duct in size, shape, density, and po-
larity. A vast majority of the cells overlying FMCLD, 
however, were morphologically similar with a spindle 
or elongated shape, and were commonly arranged as 
tongue-like projections “puncturing” into the stroma 
(Fig 1).   
 
Fig 1. Aberrant c-erbB2 expression in isolated ducts. Human breast tissue sections were double immunostained for c-erbB2 (brown 
or black) and smooth muscle actin (red). Arrows identify cell clusters with aberrant c-erbB2 expression overlying FMCLD in DCIS 
(1a-1f) and hyperplastic ducts (1g-1h). a, c, e, and g: 100X; b, d, f, and h: a higher magnification (300X) of a, c, e, and g, respectively.  Int. J. Biol. Sci. 2008, 4 
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2. Tube-like structures that resemble blood vessels: 
About 20% of c-erbB2 positive cell clusters were in 
direct continuity with tube-like structures resembling 
blood vessels (Fig 2). These tube-like structures had a 
poorly defined “wall” directly connected with the ME 
cell layer. The “wall”, however, differed from the ME 
cell layer in four main aspects: (1) it is thinner and 
elongated; (2) the lumen of these “walls” often con-
tained red blood cells (Figs 2e-2f); [3] it is weakly posi-
tive for smooth muscle actin, whereas is totally nega-
tive for p63, a nu-
clear ME cell phe-
notypic marker (Fig 
2g-2h); (4) it often 
shows distinct im-
munoreactivities to 
CD31, a endothelial 
cell specific marker. 
The frequency and 
pattern of CD31 
immunoreactivities 
in these tube-like 
structures, however, 
were not consistent 
(not shown).   
 
 
Fig 2. Aberrant c-erbB2 
expression in vessel-like 
structures. Sections a-f 
were double immu-
nostained for c-erbB2 
(brown or black) and 
smooth muscle actin 
(red). Sections g & h 
were double immu-
nostained for smooth 
muscle actin (red) and 
p63 (nuclear black 
stain). Circles identify 
c-erbB2 positive cell 
clusters and associated 
vessel-like structures. 
Thick arrows identify 
residual ME cell layers. 
Thin arrow identify ME 
cells with p63 expres-
sion. a, c, e, and g: 
100X; b, d, f, and h: a 
higher magnification 
(300X) of a, c, e, and g, 
respectively.  
 Int. J. Biol. Sci. 2008, 4 
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In addition to DCIS and hyperplastic lesions, 
elevated expression of c-erbB2 was detected in large 
clusters of morphologically normal-appearing ducts in 
7 cases. The numbers of ducts per cluster ranged from 
10 to over 50 (Fig 3). Under low magnification, these 
duct clusters were architecturally comparable to their 
adjacent normal counterparts. Under high magnifica-
tion, the ME cell layers in a vast majority of these 
ducts were attenuated, discontinuous, or totally ab-
sent. The epithelial cells of these normal-appearing 
duct clusters often displayed distinct cytological ab-
normalities, including enlarged and irregular-shaped 
nuclei, increased nuclear-cytoplasmic ratio, and sub-
stantially enlarged nucleoli, similar to those described 
in our previous report [8]. Similar to c-erbB2 positive 
malignant and hyperplastic cells, these c-erbB2 posi-
tive normal-appearing cells were also arranged as 
tongue-like projections “puncturing” deep into the 
stroma (Fig 3). These normal appearing duct clusters 
had a distinct boundary with adjacent counterparts 
that lacked c-erbB2 ex-
pression and had 
non-disrupted ME cell 
layers (Fig 3).   
 
 
 
 
 
 
Fig 3. Aberrant c-erbB2 ex-
pression in normal-appearing 
duct clusters. Human breast 
tissue sections were double 
immunostained for c-erbB2 
(brown or black) and smooth 
muscle actin (red). Arrows 
identify examples of ducts 
with aberrant c-erbB2 expres-
sion. Note that a majority of 
the ducts in some duct clusters 
are strongly positive for 
c-erbB2, whereas all ducts in 
other duct clusters are devoid 
of c-erbB2 expression. a, c, e, 
and g: 100X; b, d, f, and h: a 
higher magnification (300X) 
of a, c, e, and g, respectively.  
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In both pre-invasive and normal appearing 
ducts, cell clusters overlying FMCLD had a markedly 
higher expression of c-erbB2, compared to their adja-
cent counterparts within the same duct, but distant 
from the disruption. In all cell clusters overlying 
FMCLD, c-erbB2 expression was predominantly seen 
in the cytoplasm, despite the presence of typical cell 
membrane distribution in adjacent cells within the 
same duct but distant from the disruption (Figs.1c-1d, 
2c-2d). 
  In cases selected for real-time PCR analysis, 
c-erb2 mRNA expression in cell clusters overlying 
FMCLD was consistently higher than that of adjacent 
counterpart within the same duct, but distant from the 
disruption (Fig.4; Table 3). In 10 cases selected for 
CISH, a total of 30 small and large 
cell clusters were found to have ele-
vated atypical c-erbB2 protein ex-
pression. Of these, 23 (77%) had high 
levels of c-erbB2 gene amplification (Figs 5a-5d). High 
levels of c-erbB2 gene amplification were also seen in 
normal-appearing ducts (Figs 5e-5h). The c-erbB2 am-
plification signals were predominantly presented as 
large dot clusters (Fig 5).   
Table 3. Real-time PCR outcomes 
Sample  Average Ct of tar-
get gene 
Average Ct of 
control gene 
∆Ct  ∆∆Ct Fold of 
change 
1A Undetermined*  35.78       
1B 31.12  35.55       
2A 37.36  35.27  2.09     
2B 27.56  35.03  -7.74 -9.83 910 
3A Undetermined*  36.12       
3B 36.25  36.78       
 
 
 
 
 
 
 
 
Fig 4. Cell clusters dissected for real-time 
PCR and the PCR results of a selected case 
(case 2). Human breast tissue sections were 
double immunostained for c-erbB2 (brown 
or black) and smooth muscle actin (red). 
Thick arrows identify c-erbB2 positive cell 
clusters overlying FMCLD. Thin arrows 
identify residual ME cell layers. Curves 
show c-erbB2 mRNA levels between cell 
clusters overlying FMCLD (2b) and adja-
cent counterparts (2a) within the same duct. 
Each datum set was analyzed in triplicate.   
 Int. J. Biol. Sci. 2008, 4 
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Fig 5. C-erbB2 amplification in cell clusters overlying FMCLD and in normal appearing ducts. Two sets (a-d and e-h) of adjacent 
sections were subjected to double immunohistochemical staining (a-b & e-f) and CISH (c-d & g-h). Arrows identify cell clusters 
with aberrant c-erbB2 protein expression and high level of c-erbB2 gene amplification in DCIS (a-d) and normal appearing ducts 
(e-h). a, c, e, and g:100X; b, d, f, and h: a higher magnification (300X) of a, c, e, and g, respectively. Int. J. Biol. Sci. 2008, 4 
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Discussion 
Our current study detected significantly higher 
c-erbB2 protein expression and gene amplification in 
malignant and hyperplastic cell clusters overlying 
FMCLD than that in adjacent cells within the same 
duct, but distant from the disruption, and also in 
morphologically normal-appearing duct clusters with 
distinct cytological abnormalities in their surrounding 
ME cell layers and epithelial cells. To our best knowl-
edge, these findings have not been previously re-
ported. The main reasons appear to be: (1) these clus-
ters are indistinguishable from their clear-cut normal 
counterparts under low magnification of H&E sec-
tions, which allow them to escape from detection, (2) 
the size of these clusters are relatively small and could 
be elucidated only by double immunohistochemistry, 
which has not been widely used in clinical samples, 
and (3) past studies has been focused primarily on the 
membrane expression of c-erbB2.   
Aberrant c-erbB2 expression in cell clusters 
overlying FMCLD is likely to result from or to signify 
the emergence of biologically more aggressive cell 
clones for three reasons. First, c-erbB2 expression is 
absolutely required for breast morphogenesis and an-
giogenesis [35]. The absence of c-erbB2 expression 
could result in a number of structural defects, includ-
ing a significant reduction of the epithelial cells in the 
terminal duct-lobular units [36]. The c-erbB2 and 
c-met signaling pathways are also required for the 
branching and alveolar morphogenesis, by regulating 
the breakdown of intercellular junctions and shift of 
the sub-cellular localization of the cell adhesion 
molecules, so that epithelial cells could migrate to new 
destinations to form new structures [37-38]. Second, as 
the epithelium is normally devoid of vascular struc-
tures and the ME cell layer is the sole source of several 
tumor suppressors, a FMCLD could result in several 
focal alterations: (1) a loss of tumor suppressors and 
paracrine inhibitory functions, which allow epithelial 
cells to escape from programmed cell death, (2) altera-
tions in permeability for oxygen or growth factors, 
which selectively favor the exit of stem cells from qui-
escence and monoclonal proliferation of the progeni-
tor cells, and (3) direct exposure of the epithelial cells 
to stromal and immunoreactive cells, which stimulates 
tumor angiogenesis and epithelial-mesenchymal tran-
sition [39-41]. The above alterations may individually 
or collectively induce the emergence of biologically 
more aggressive cell clones and aberrant c-erbB2 ex-
pression. Consistent with this possibility is the fact 
that c-erbB2 expression is inducible by a number of 
factors, including ultraviolet irradiation, hormonal 
receptors, or developmental stages [43-44]. Third, our 
recent studies have consistently shown that cell clus-
ters overlying FMCLD are biologically more aggres-
sive, as they have a significantly higher frequency of 
ER negativity, genetic instabilities, and expression of 
tumor invasion-related genes than adjacent cells 
within the same duct [16-26]. Our findings are in 
agreement with that of a previous study, which shows 
that microdissected cells from the periphery of DCIS 
have significantly higher gene expression than their 
counterparts in the center of the same DCIS, assessed 
with Atlas human Cancer 1.2 Arrays, which contain 
1176 known cancer-related genes [42].   
Aberrant c-erbB2 expression in normal appearing 
duct clusters is likely to result from two factors. First, 
these clusters may present a population of maturation 
arrested progenitors derived from monoclonal prolif-
eration of genetically damaged primitive stem cells at 
the early stages of ductal morphogenesis by trauma, 
radiation, or other factors [45]. These clusters may re-
tain the potential for unlimited proliferation and 
multi-lineage differentiation by recapitulation of the 
process of duct branching and morphogenesis. Since 
duct branching and tumor invasion share a very simi-
lar molecular mechanism [36-38], aberrant c-erbB2 
expression in these normal appearing duct clusters is 
likely to be associated with, or reflect these events. 
Second, these clusters may represent a previously un-
characterized malignant lesion with genetic defects in 
the c-erbB2 gene. In agreement with this possibility is 
the fact that “clinging ductal carcinoma in situ” is 
morphologically indistinguishable to normal ducts 
under low magnification of H&E stained sections, but 
microdissected cells from this lesion share the same 
genetic instabilities and the same monoclonality with 
invasive cancers [6, 46].  This possibility is further 
supported by the fact that recent studies have identi-
fied a DNA phenotype, which is identical to that of 
invasive prostate cancer in certain healthy men and 
also in morphologically normal tissues adjacent to 
prostate cancer [47-49]. Previous studies have shown 
that a point mutation in the transmembrane domain 
could alter the protein’s helical structure and it’s in-
sertion into the cell membrane [50]. Mutations also 
alter the subcellular localization of coded proteins and 
the biological functions of the c-erbB2 protein [51-52].   
The scientific and clinical significance of cyto-
plasmic c-erbB2 expression has been a subject of de-
bate. Based on data derived from immunohisto-
chemical staining and in situ hybridization, Taylor et 
al stated that “cytoplasmic staining for c-erbB2 is an 
immunocytochemical artifact” with no significant im-
plication [53, 54]. In sharp contrast, a number of stud-
ies have shown that cytoplasmic expression of c-erbB2 
is significantly associated with worse prognosis in Int. J. Biol. Sci. 2008, 4 
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breast, endometrial, and other carcinomas [55,56]. Our 
findings differ from those of the above reports in two 
main aspects: (1) cytoplasmic c-erbB2 expression is 
exclusively or preferentially associated with cells 
overlying FMCLD, and (2) cells with cytoplasmic 
c-erbB2 expression also show appreciable membra-
nous c-erbB2 expression.   
The scientific and clinical significance of our 
findings cannot be determined at present, since the 
sample size of our study is small, and the clinical fol-
low-up data are not available. On the other hand, it is 
clear that cell clusters overlying FMCLD have signifi-
cantly higher aberrant c-erbB2 expression than their 
adjacent counterparts within the same duct. Coupled 
with a significantly higher rate of ER negativity, ge-
netic instabilities, and expression of tumor invasion 
related genes [18-26], it is very likely that aberrant 
c-erbB2 expression in these cell clusters is associated 
with, or signifies the emergence of biologically more 
aggressive cell clones. Consequently, patients with 
DCIS  that have aberrant c-erbB2 expression in cell 
clusters overlying FMCLD are very likely to represent 
the specific individual who will develop, or at greater 
risk to develop, invasive breast lesions. If confirmed 
by studies in more cases and by clinical follow-up 
data, our findings and technical approaches may have 
significant value in predication of tumor progression 
or invasion, and in selection of patients for optimal 
treatment.  
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